Technology Listings


62 Results Sort By:
Engineering Tighter Binding Spherical Nucleic Acids
Application Method to enhance the affinity of spherical nucleic acids for their targets. Key Benefits Facile method for molecular printing on surface of NP. Massive improvement of SNA’s binding affinity to the target can provide strategies in applications for therapeutics and diagnostics. May maximize DNA density on the NP surface. Market...
Published: 11/2/2020       Contributor(s):  
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease. Key Benefits Provides a cardio-protective benefit in CKD patients. Suppresses cardiac hypertrophy and fibrosis. Market Summary Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 11/2/2020       Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients. Key Benefits Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020       Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
Small Molecule for Treatment of Alzheimer’s Disease and Cancer
Application New family of AEP inhibitors for neurodegenerative diseases or cancer. Key Benefits Non peptide, small molecule inhibitor of AEP. Alzheimer candidate is Blood-Brain Barrier (BBB) permeable. AEP inhibitors are a potential candidate for AD and cancer. Market Summary Alzheimer’s disease (AD) is the most common dementia affecting...
Published: 10/1/2020       Contributor(s): Keqiang Ye
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease. Key Benefits Provides a cardio-protective benefit in CKD patients. Suppresses cardiac hypertrophy and fibrosis. Market Summary Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 6/15/2020       Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
Plant-Based Small Molecules for Treatment of MRSA Infections
Application Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Key Benefits Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance. Does not harm beneficial host bacteria. May potentially be used concomitantly...
Published: 4/23/2020       Contributor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer. Key Benefits Novel molecule. Novel target presents new path to lung cancer treatment. Potentially extend survival rate of lung cancer patients. Market Summary Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020       Contributor(s): Xingming Deng
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells. Key Benefits Nearly limitless supply of source cells. Non-invasive method for harvesting source cells. Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020       Contributor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
Small Molecule for Treatment-Resistant Lung Cancer
Application Small molecule agonist for treating cancers involving KRAS mutations. Key Benefits Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC). Selective for mutant KRAS lung cancer cells over normal cells. Non-toxic to normal cells. Market Summary Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020       Contributor(s): Xingming Deng
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders. Key Benefits Specifically targets NMDARs that contain the GluN2C/2D subunit. Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators. Market...
Published: 1/10/2020       Contributor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
1 2 3 4 5 6 7